NanoR

The funded “NanoR” project by 4base lab AG has set out to develop new approaches for the testing and quality control of mRNA-based vaccines, with the aim of reducing the error rates for synthesised mRNA and improving their quality. The quality of the mRNA is crucial for its stability and is therefore also responsible for how it behaves and initiates a response in patients.

4base lab AG is a biotech company based in Technologiepark Reutlingen that has been involved in developing and manufacturing mRNA vaccines against carcinogens and infectious agents since 2005. The company is accredited or certified to various regulatory standards such as GMP standards, DIN EN ISO 9001:2015, DIN EN ISO 14001:2015 and DIN EN ISO/IEC 17025:2018.

It offers extensive expertise in analytical requirements for testing the quality and identity of these molecules and validating them across the entire development and production process for this innovative class of medicinal products.